http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ce3d73e7123a6fedb4339a3fe0a780b1
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Davids |
| name | Matthew S. Davids Matthew S Davids |
| given-name | Matthew S. Matthew S |
| organization-name | Dana‐Farber Cancer Institute Boston MA Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 8Department of Medicine, Brigham and Women’s Hospital, Boston, MA Harvard Medical School, Boston, Massachusetts. Division of Lymphoma, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Andrew W. Roberts, John F. Seymour, and Mary Ann Anderson, University of Melbourne; Andrew W. Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research; and John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; John M. Pagel, Swedish Cancer Institute, Seattle, WA; Brad S. Kahl, Washington University Medical School, St Louis, MO; William G. Wierda, University of Texas MD... Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 3Harvard Medical School, Boston, Massachusetts.; 16Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C.... Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;; Medicine, Harvard Medical School, Boston, MA, USA; Department of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA;; Brigham and Women’s Hospital, Boston, MA;; Harvard Medical School, Boston, MA; and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Dana Farber Cancer Institute, Boston, MA, USA Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;; Harvard Medical School, Boston, MA, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Dana-Farber Cancer Institute Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA; Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James’s University Hospital,... Dana-Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA 4Dana Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA;; Department of Medicine, Brigham and Women’s Hospital, Boston, MA DANA-FARBER CANCER INSTITUTE Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA. Electronic address: [email protected]. Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of... Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Bing Center for Waldenstrom's Macroglobulinemia Dana Farber Cancer Institute Boston MA USA; Department of Medicine Harvard Medical School Boston MA USA 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Write Affiliation text here. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 5Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Dana‐Farber/Brigham and Womenʼs Cancer Center Boston Massachusetts USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Division of Lymphoma, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. 1Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber/Partners CancerCare, Boston, MA; Department of Haematology/Oncology, National University Health System, Singapore, Singapore. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 9Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA All authors: Dana-Farber Cancer Institute, Boston, MA. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA 10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.). 14Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Authors' Affiliation: Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Dana-Farber Cancer Institute, Boston, Massachusetts, United States 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachuetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: [email protected]. Harvard Medical School Boston Massachusetts; Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts Departments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA; Departments of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA 2Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. |
Incoming Links
Showing number of triples: 1 to 210 of 210.